乳腺癌：潜在耐药的分子机制与治疗方法
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
作者信息
Tufail Muhammad, Cui Jia, Wu Changxin
机构信息
Institute of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China.
Department of Microbiology, Changzhi Medical College Changzhi 046000, Shanxi, China.
出版信息
Am J Cancer Res. 2022 Jul 15;12(7):2920-2949. eCollection 2022.
Abstract
Breast cancer (BC) affects over 250,000 women in the US each year. Drug-resistant cancer cells are responsible for most breast cancer fatalities. Scientists are developing novel chemotherapeutic drugs and targeted therapy combinations to overcome cancer cell resistance. Combining drugs can reduce the chances of a tumor developing resistance to treatment. Clinical research has shown that combination chemotherapy enhances or improves survival, depending on the patient's response to treatment. Combination therapy is a highly successful supplemental cancer treatment. This review sheds light on intrinsic resistance to BC drugs and the importance of combination therapy for BC treatment. In addition to recurrence and metastasis of BC, the article discussed biomarkers for BC.
摘要
乳腺癌（BC）每年在美国影响超过25万名女性。耐药癌细胞是大多数乳腺癌死亡的原因。科学家们正在开发新型化疗药物和靶向治疗组合，以克服癌细胞的耐药性。联合用药可以降低肿瘤产生治疗耐药性的几率。临床研究表明，联合化疗能否提高或改善生存率，取决于患者对治疗的反应。联合治疗是一种非常成功的辅助癌症治疗方法。这篇综述揭示了对乳腺癌药物的内在耐药性以及联合治疗对乳腺癌治疗的重要性。除了乳腺癌的复发和转移，本文还讨论了乳腺癌的生物标志物。
相似文献
1
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.乳腺癌：潜在耐药的分子机制与治疗方法
Am J Cancer Res. 2022 Jul 15;12(7):2920-2949. eCollection 2022.
2
The Breast Cancer Stem Cells Traits and Drug Resistance.乳腺癌干细胞特性与耐药性
Front Pharmacol. 2021 Jan 28;11:599965. doi: 10.3389/fphar.2020.599965. eCollection 2020.
3
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
4
Breast cancer under age 40: a different approach.40岁以下乳腺癌：一种不同的治疗方法。
Curr Treat Options Oncol. 2015 Apr;16(4):16. doi: 10.1007/s11864-015-0334-8.
5
Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.TWIST小干扰RNA和抗癌药物的纳米颗粒递送：一种抗癌治疗方法
Enzymes. 2018;44:83-101. doi: 10.1016/bs.enz.2018.08.004. Epub 2018 Oct 5.
6
Evolving standards of care and new challenges in the management of HER2-positive breast cancer.不断发展的 HER2 阳性乳腺癌治疗标准和新挑战。
CA Cancer J Clin. 2020 Sep;70(5):355-374. doi: 10.3322/caac.21634. Epub 2020 Aug 19.
7
Breast Cancer Response to Therapy: Can microRNAs Lead the Way?乳腺癌治疗反应：微小 RNA 能否引领前路？
J Mammary Gland Biol Neoplasia. 2021 Jun;26(2):157-178. doi: 10.1007/s10911-021-09478-3. Epub 2021 Jan 21.
8
Resistance to Targeted Therapies in Breast Cancer.乳腺癌对靶向治疗的耐药性
Methods Mol Biol. 2016;1395:105-36. doi: 10.1007/978-1-4939-3347-1_8.
9
Resistance and Overcoming Resistance in Breast Cancer.乳腺癌中的耐药性与克服耐药性
Breast Cancer (Dove Med Press). 2020 Nov 11;12:211-229. doi: 10.2147/BCTT.S270799. eCollection 2020.
10
CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.CD24在三阴性乳腺癌中的表达及对化疗的差异耐药性
Oncotarget. 2017 Jun 13;8(24):38294-38308. doi: 10.18632/oncotarget.16203.
引用本文的文献
1
Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells.靶向铁调节蛋白2（IRP2）以破坏铁代谢，通过乳腺癌细胞中的线粒体功能障碍增强放射敏感性。
Cell Death Discov. 2025 Jul 31;11(1):357. doi: 10.1038/s41420-025-02653-z.
2
Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment and monitoring.乳腺癌的液体活检：循环肿瘤DNA和循环肿瘤细胞在诊断、治疗及监测中的临床意义
Mol Cell Biochem. 2025 Jun 30. doi: 10.1007/s11010-025-05343-7.
3
PLCH1 overexpression promotes breast cancer progression and predicts poor prognosis through the ERK1/2-EGR1 axis.PLCH1过表达通过ERK1/2-EGR1轴促进乳腺癌进展并预示不良预后。
Front Oncol. 2025 May 30;15:1577114. doi: 10.3389/fonc.2025.1577114. eCollection 2025.
4
Regulation of PEST-containing nuclear proteins in cancer cells: implications for cancer biology and therapy.癌细胞中含PEST核蛋白的调控：对癌症生物学和治疗的意义。
Front Oncol. 2025 Apr 22;15:1548886. doi: 10.3389/fonc.2025.1548886. eCollection 2025.
5
Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies.液体活检追踪分子靶向乳腺癌治疗耐药性的当前趋势
Genes (Basel). 2025 Apr 9;16(4):443. doi: 10.3390/genes16040443.
6
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies.乳腺癌的分子亚型与机制：靶向治疗的精准医学方法
Cancers (Basel). 2025 Mar 25;17(7):1102. doi: 10.3390/cancers17071102.
7
Predictive Value of Gene Expression in Chemotherapy Response in Breast Cancer.基因表达对乳腺癌化疗反应的预测价值
Pharmaceuticals (Basel). 2025 Feb 8;18(2):235. doi: 10.3390/ph18020235.
8
Nanoscale strategies: doxorubicin resistance challenges and enhancing cancer therapy with advanced nanotechnological approaches.纳米尺度策略：阿霉素耐药性挑战以及利用先进纳米技术方法增强癌症治疗效果
Drug Deliv Transl Res. 2025 Feb 15. doi: 10.1007/s13346-025-01790-3.
9
Let-7b-5p sensitizes breast cancer cells to doxorubicin through Aurora Kinase B.Let-7b-5p通过极光激酶B使乳腺癌细胞对阿霉素敏感。
PLoS One. 2025 Jan 9;20(1):e0307420. doi: 10.1371/journal.pone.0307420. eCollection 2025.
10
Modeling intratumor heterogeneity in breast cancer.乳腺癌肿瘤内异质性建模
Biofabrication. 2024 Dec 19;17(1). doi: 10.1088/1758-5090/ad9b50.
本文引用的文献
1
Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer.用于鉴定乳腺癌临床生物标志物的药物代谢。
Int J Mol Sci. 2022 Mar 16;23(6):3181. doi: 10.3390/ijms23063181.
2
Breast Cancer Treatment.乳腺癌治疗。
Am Fam Physician. 2021 Aug 1;104(2):171-178.
3
Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis.乳腺癌隐匿性淋巴结转移的预后意义：一项荟萃分析。
BMC Cancer. 2021 Jul 30;21(1):875. doi: 10.1186/s12885-021-08582-1.
4
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.多西他赛与长春瑞滨联合曲妥珠单抗和帕妥珠单抗用于转移性 HER2 阳性乳腺癌一线治疗：一项回顾性的两中心研究。
Breast Cancer Res Treat. 2021 Jul;188(2):379-387. doi: 10.1007/s10549-021-06198-4. Epub 2021 Mar 27.
5
Human Microbiota and Breast Cancer-Is There Any Relevant Link?-A Literature Review and New Horizons Toward Personalised Medicine.人类微生物群与乳腺癌——是否存在相关联系？——文献综述及个性化医学的新视野
Front Microbiol. 2021 Feb 25;12:584332. doi: 10.3389/fmicb.2021.584332. eCollection 2021.
6
DNA Repair Pathways in Cancer Therapy and Resistance.癌症治疗与耐药中的DNA修复途径
Front Pharmacol. 2021 Feb 8;11:629266. doi: 10.3389/fphar.2020.629266. eCollection 2020.
7
Modes of Regulated Cell Death in Cancer.癌症中细胞程序性死亡的方式
Cancer Discov. 2021 Feb;11(2):245-265. doi: 10.1158/2159-8290.CD-20-0789. Epub 2021 Jan 18.
8
Steps in metastasis: an updated review.转移步骤：最新综述。
Med Oncol. 2021 Jan 4;38(1):3. doi: 10.1007/s12032-020-01447-w.
9
Axillary surgery for breast cancer: past, present, and future.乳腺癌腋窝手术：过去、现在与未来。
Breast Cancer. 2021 Jan;28(1):9-15. doi: 10.1007/s12282-020-01120-0. Epub 2020 Nov 9.
10
Androstano-arylpyrimidines: Novel small molecule inhibitors of MDR1 for sensitizing multidrug-resistant breast cancer cells.雄甾烷芳基嘧啶：用于使多药耐药乳腺癌细胞致敏的新型MDR1小分子抑制剂。
Eur J Pharm Sci. 2021 Jan 1;156:105587. doi: 10.1016/j.ejps.2020.105587. Epub 2020 Oct 8.
Zotero 插件